Other News To Note

• Ligand Pharmaceuticals Inc., of San Diego, said partner Pfizer Inc., of New York, reported that the European Medicines Agency accepted for review the marketing authorization application for bazedoxifene/conjugated estrogens (BZA/CE), under review for use in postmenopausal women with a uterus for treating estrogen deficiency symptoms and treating osteoporosis in women at risk of fracture. Pfizer expects a decision in 2013.